15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 22 firms covering BridgeBio Pharma Inc, 20 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $93.00 to $130.00, so the covering firms are broadly aligned. The average target of $106.83 sits 25% above the current $85.55. The rating mix has stayed broadly stable, with Buy-side ratings easing from 24 to 20 over recent months. On the fundamentals, the Street sees revenue growth near 90% this year and 70% next, consensus EPS building from about $-0.47 next quarter toward $0.57 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS22 ratings
Strong Buy
Strong Buy00%
Buy2091%
Hold29%
Sell00%
Strong Sell00%
Based on 22 analysts giving stock ratings to BridgeBio Pharma Inc.
As of Jul, 20 of 22 firms rate BBIO a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BBIO EPS & revenue forecast
EPS · NEXT QUARTER
$-0.47
Range $-0.59 – $-0.34 · 7 analysts · -35% YoY
Next period, 7 analysts expect BridgeBio Pharma Inc to earn $-0.47 a share (range $-0.59 – $-0.34), versus $-0.72 a year earlier. Full-year consensus is $-2.14, growing to $0.57 the year after.
REVENUE · NEXT QUARTER
$252.0M
Range $228.2M – $285.0M · 7 analysts · +108% YoY
Revenue is expected to reach $252.0M (range $228.2M – $285.0M), +108.0% year-over-year. Full-year consensus is $961.2M, rising to $1.6B next year.
Top analysts covering BridgeBio Pharma Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBIO.
#1
Anupam Rama
JP Morgan · Rank #62
Buy
$100.00+16.9% to target
Overall win rate
46%
+ Follow
#2
Greg Harrison
Scotiabank · Rank #177
Buy
$57.00-33.4% to target
Overall win rate
38%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$120.00+40.3% to target
Overall win rate
37%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #350
Buy
$98.00+14.6% to target
Overall win rate
32%
+ Follow
#5
EJ
Eric Joseph
Citi
Hold
$93.00+8.7% to target
Coverage
—
+ Follow
BBIO stock forecast FAQ
What is BBIO's average 12-month price target?+
The 6 analysts with a live target average $106.83 for BridgeBio Pharma Inc over the next 12 months, ranging from a $130.00 high to a $93.00 low.
Is BBIO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 22 analyst ratings, 20 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BBIO?+
The Street-high target is $130.00 (Evercore ISI Group), and the Street-low is $93.00 (Citigroup). The average of all 6 active targets is $106.83.
How many Wall Street analysts cover BBIO?+
22 analysts have an active rating on BridgeBio Pharma Inc, and 6 firms carry a live 12-month price target.
Who is the most accurate analyst covering BBIO?+
Among analysts who currently cover BBIO, Anupam Rama of JP Morgan has the strongest overall Quantellect track record (Rank #62). Their current call is Buy with a $100.00 target.
What is BridgeBio Pharma Inc's projected EPS for next quarter?+
The consensus estimate is $-0.47 per share (range $-0.59 – $-0.34) across 7 analysts. Full-year EPS is projected at $-2.14, rising to $0.57 the following year.
How much revenue is BridgeBio Pharma Inc expected to report next quarter?+
Consensus revenue is $252.0M (range $228.2M – $285.0M). Full-year revenue is projected at $961.2M, growing to $1.6B next year.
Have analysts been upgrading or downgrading BBIO lately?+
As of Jul, 20 of 22 firms rate BBIO a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
